v3.26.3
Other (Income)/Deductions—Net - Schedule of Impaired Intangible Assets (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 27, 2026
Sep. 28, 2025
Intangible Asset, Finite-Lived [Line Items]    
Total [1] $ 5,600  
Impairment 4,325  
Developed technology rights [Member]    
Intangible Asset, Finite-Lived [Line Items]    
Developed technology rights [1],[2] 0  
Impairment [2] 525  
IPR&D [Member]    
Intangible Asset, Finite-Lived [Line Items]    
Indefinite-lived [1],[2] 5,600  
Impairment 3,800 [2] $ 210
Level 1 [Member]    
Intangible Asset, Finite-Lived [Line Items]    
Total [1] 0  
Level 1 [Member] | Developed technology rights [Member]    
Intangible Asset, Finite-Lived [Line Items]    
Developed technology rights [1],[2] 0  
Level 1 [Member] | IPR&D [Member]    
Intangible Asset, Finite-Lived [Line Items]    
Indefinite-lived [1],[2] 0  
Level 2 [Member]    
Intangible Asset, Finite-Lived [Line Items]    
Total [1] 0  
Level 2 [Member] | Developed technology rights [Member]    
Intangible Asset, Finite-Lived [Line Items]    
Developed technology rights [1],[2] 0  
Level 2 [Member] | IPR&D [Member]    
Intangible Asset, Finite-Lived [Line Items]    
Indefinite-lived [1],[2] 0  
Level 3 [Member]    
Intangible Asset, Finite-Lived [Line Items]    
Total [1] 5,600  
Level 3 [Member] | Developed technology rights [Member]    
Intangible Asset, Finite-Lived [Line Items]    
Developed technology rights [1],[2] 0  
Level 3 [Member] | IPR&D [Member]    
Intangible Asset, Finite-Lived [Line Items]    
Indefinite-lived [1],[2] $ 5,600  
[1] The fair value amount reflects the remaining fair value for the asset that has been impaired as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See Note 1E in our 2025 Form 10-K.
[2] Reflects intangible assets written down to fair value in 2026. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory factors on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.